Checkpoint Therapeutics Stock Probability of Future Stock Price Finishing Under 3.84
| CKPT Stock | USD 4.28 0.18 4.39% |
Checkpoint |
Checkpoint Therapeutics Target Price Odds to finish below 3.84
The tendency of Checkpoint Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 3.84 or more in 90 days |
| 4.28 | 90 days | 3.84 | more than 94.0 |
Based on a normal probability distribution, the odds of Checkpoint Therapeutics to drop to $ 3.84 or more in 90 days from now is more than 94.0 (This Checkpoint Therapeutics probability density function shows the probability of Checkpoint Stock to fall within a particular range of prices over 90 days) . Probability of Checkpoint Therapeutics price to stay between $ 3.84 and its current price of $4.28 at the end of the 90-day period is nearly 4.82 .
Given the investment horizon of 90 days Checkpoint Therapeutics has a beta of 0.34 suggesting as returns on the market go up, Checkpoint Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Checkpoint Therapeutics will be expected to be much smaller as well. Moreover Checkpoint Therapeutics has an alpha of 1.0104, implying that it can generate a 1.01 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Checkpoint Therapeutics Price Density |
| Price |
Predictive Modules for Checkpoint Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Checkpoint Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Checkpoint Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Checkpoint Therapeutics is not an exception. The market had few large corrections towards the Checkpoint Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Checkpoint Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Checkpoint Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.01 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 0.64 | |
Ir | Information ratio | 0.23 |
Checkpoint Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Checkpoint Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Checkpoint Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Checkpoint Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (48.19 M). | |
| Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Acquisition by Howson Tamar D of 10000 shares of Cue Biopharma subject to Rule 16b-3 |
Checkpoint Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Checkpoint Stock often depends not only on the future outlook of the current and potential Checkpoint Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Checkpoint Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18.7 M | |
| Cash And Short Term Investments | 4.9 M |
Checkpoint Therapeutics Technical Analysis
Checkpoint Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Checkpoint Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Checkpoint Therapeutics. In general, you should focus on analyzing Checkpoint Stock price patterns and their correlations with different microeconomic environments and drivers.
Checkpoint Therapeutics Predictive Forecast Models
Checkpoint Therapeutics' time-series forecasting models is one of many Checkpoint Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Checkpoint Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Checkpoint Therapeutics
Checking the ongoing alerts about Checkpoint Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Checkpoint Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Checkpoint Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (48.19 M). | |
| Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Acquisition by Howson Tamar D of 10000 shares of Cue Biopharma subject to Rule 16b-3 |
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.